Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review

Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on March 31, 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.

Download Full-text

Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.04.020 ◽

2021 ◽

Author(s):

Christine Fribert Thusgaard ◽

Malene Korsholm ◽

Kristina Magaard Koldby ◽

Torben A. Kruse ◽

Mads Thomassen ◽

...

Keyword(s):

Systematic Review ◽

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Circulating Tumor Dna ◽

Tumor Dna

Download Full-text

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Scientific Reports ◽

10.1038/s41598-018-35524-y ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 3

Author(s):

Francesco Passiglia ◽

Sergio Rizzo ◽

Massimo Di Maio ◽

Antonio Galvano ◽

Giuseppe Badalamenti ◽

...

Keyword(s):

Systematic Review ◽

Diagnostic Accuracy ◽

Meta Analysis ◽

Circulating Tumor Dna ◽

T790m Mutation ◽

Tumor Dna ◽

Egfr T790m

Download Full-text

Prognostic value of baseline and 3 months postoperative circulating tumor DNA (ctDNA) in ovarian cancer patients

10.3802/jgo.2021.32.s1.o14 ◽

2021 ◽

Author(s):

Yoo-Na Kim ◽

Jinho Heo ◽

Jung-Yun Lee ◽

Seung-Tae Lee ◽

Saeam Shin ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Circulating Tumor Dna ◽

Tumor Dna

Download Full-text

Circulating tumor DNA as a marker of residual tumor in colon cancer

Colorectal Oncology ◽

10.17650/2220-3478-2018-8-3-11-16 ◽

2018 ◽

Vol 8 (3) ◽

pp. 11-16

Author(s):

M. Yu. Fedyanin ◽

Kh. Kh.-M. Elsnukaeva ◽

V. A. Aliev ◽

T. S. Ayrapetyan ◽

A. V. Polyakov ◽

...

Keyword(s):

Colon Cancer ◽

Malignant Tumors ◽

Malignant Neoplasm ◽

Residual Tumor ◽

Circulating Tumor Dna ◽

Theoretical Background ◽

National Medical ◽

Fundamental Medicine ◽

Tumor Dna ◽

Predict Disease Progression

Colon cancer is the 3rdmost common malignant neoplasm and the 4thleading cause of mortality from them. The majority of patients are diagnosed at stages II–IV, which indicates the need for markers that can predict disease progression, especially after surgical treatment. Recently, there has been a growing interest in exploring circulating tumor DNA as a marker of residual tumor in colon cancer. In 2018, the N.N. Blokhin National Medical Research Center of Oncology together with the Institute of Chemical Biology and Fundamental Medicine under the coordination of the Center for Strategic Planning and Management of Biomedical Health Risks initiated a research project entitled “Development of an assay for the diagnosis of various malignant tumors and treatment efficacy monitoring based on the analysis of circulating tumor DNA from patient blood”. This article provides a theoretical background for the project and a report on its progress made so far.

Download Full-text